Clinical trial
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)
NCT07930637 is registered in ClinicalTrials.gov with Sinfatin S.L as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)
- Lead sponsor
- Sinfatin S.L
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 6, 2026
- Completion date
- March 31, 2028
- Enrollment
- 80 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
post-covid-19 syndrome
Arms
As registered; 2 arms.
-
Rimonabant 5 mg
Participants receive rimonabant 5 mg orally once daily for 90 days.
-
Placebo
Participants receive matching placebo orally once daily for 90 days.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Symbol Digit Modalities Test (SDMT)
The SDMT assesses cognitive processing speed using the validated Spanish version of the test. Participants must match symbols to their corresponding numbers within 90 seconds. The raw score is the number of correct responses, ranging from 0 to 110; higher scores indicate better performance. Age- and education-adjusted scores are calculated using Spanish normative data.
Lead sponsor's other trials
Sinfatin S.L, most recent start first.
Similar trials
Same condition (Post-Acute COVID-19 Syndrome) and phase, most recent start first.
+72 more trials See the condition page